Evaluation of the effect of low-dose lung radiotherapy in the treatment of Covid 19

Comparative study of the effectiveness of low-dose lung radiation in comparison with placebo in the treatment of cancer patients with severe inflammatory phase of covid19 pneumonia

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201203049585N2

Enrollment

Registered

2021-09-21

Start date

2021-09-05

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19 Pneumonia. Pneumonia due to SARS-associated coronavirus

Interventions

Intervention 1: Intervention group: Radiotherapy of both whole lungs in one fraction( a regular single session of radiotherapy) and at a dose of 5 Gy with treatment design by radiation-oncologist and

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Over 18 years Having cancer Covid-19 pneumonia that has been confirmed by PCR test Lung involvement more than 50% that has been confirmed by HRCT Interleukin-6 = 40 or establishing two of the following criteria: D-dimmer = 1000 CRP = 100 LDH = 300 Ferritin = 500 Not a candidate for ICU admission

Exclusion criteria

Exclusion criteria: Any contraindication for radiotherapy Current chest radiotherapy Active pulmonary metastasis A history of previous lung radiotherapy Being pregnant The patient's WBC be less than 1000 in the day before the intervention Unable to understand the conditions of the intervention, in the terms of mental health

Design outcomes

Primary

Measure	Time frame
Percentage of lung involvement on CT scan after treatment. Timepoint: At the beginning of the study and two months after radiotherapy. Method of measurement: High-resolution lung CT scan without contrast.	—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: During the patient's stay in the hospital. Method of measurement: The patient's hospital record.;Reduction of IL-6. Timepoint: At the beginning of the study and two months after radiotherapy. Method of measurement: Laboratory tests.;Reduction of CRP. Timepoint: At the beginning of the study and two months after radiotherapy. Method of measurement: Laboratory tests.;Reduction of D-dimmer. Timepoint: At the beginning of the study and two months after radiotherapy. Method of measurement: Laboratory tests.;Reduction of LDH. Timepoint: At the beginning of the study and two months after radiotherapy. Method of measurement: Laboratory tests.;Reduction of Ferritin. Timepoint: At the beginning of the study and two months after radiotherapy. Method of measurement: Laboratory tests.	—

Measure

Time frame

Duration of hospitalization. Timepoint: During the patient's stay in the hospital. Method of measurement: The patient's hospital record.;Reduction of IL-6. Timepoint: At the beginning of the study and two months after radiotherapy. Method of measurement: Laboratory tests.;Reduction of CRP. Timepoint: At the beginning of the study and two months after radiotherapy. Method of measurement: Laboratory tests.;Reduction of D-dimmer. Timepoint: At the beginning of the study and two months after radiotherapy. Method of measurement: Laboratory tests.;Reduction of LDH. Timepoint: At the beginning of the study and two months after radiotherapy. Method of measurement: Laboratory tests.;Reduction of Ferritin. Timepoint: At the beginning of the study and two months after radiotherapy. Method of measurement: Laboratory tests.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNadia Najafizade

Esfahan University of Medical Sciences

nadianajafizade@yahoo.com+98 31 3236 8006

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026